

21 **Abstract**

22 **Background:** At present, PCR-based nucleic acid detection cannot meet the demands
23 for coronavirus infectious disease (COVID-19) diagnosis.

24 **Methods:** 214 confirmed COVID-19 patients who were hospitalized in the General
25 Hospital of Central Theater Command of the People's Liberation Army between
26 January 18 and February 26, 2020, were recruited. Two Enzyme-Linked
27 Immunosorbent Assay (ELISA) kits based on recombinant SARS-CoV-2 nucleocapsid
28 protein (rN) and spike protein (rS) were used for detecting IgM and IgG antibodies,
29 and their diagnostic feasibility was evaluated.

30 **Results:** Among the 214 patients, 146 (68.2%) and 150 (70.1%) were successfully
31 diagnosed with the rN-based IgM and IgG ELISAs, respectively; 165 (77.1%) and
32 159 (74.3%) were successfully diagnosed with the rS-based IgM and IgG ELISAs,
33 respectively. The positive rates of the rN-based and rS-based ELISAs for antibody
34 (IgM and/or IgG) detection were 80.4% and 82.2%, respectively. The sensitivity of
35 the rS-based ELISA for IgM detection was significantly higher than that of the
36 rN-based ELISA. We observed an increase in the positive rate for IgM and IgG with
37 an increasing number of days post-disease onset (d.p.o.), but the positive rate of IgM
38 dropped after 35 d.p.o. The positive rate of rN-based and rS-based IgM and IgG
39 ELISAs was less than 60% during the early stage of the illness 0-10 d.p.o., and that of
40 IgM and IgG was obviously increased after 10 d.p.o.

41 **Conclusions:** ELISA has a high sensitivity, especially for the detection of serum
42 samples from patients after 10 d.p.o, it can be an important supplementary method for

43 COVID-19 diagnosis.

44 **Key words:** COVID-19 diagnosis; ELISA; antibody; IgM; IgG; nucleocapsid protein;

45 spike protein.

46 **Introduction**

47 The ongoing outbreak of coronavirus infectious disease 2019 (COVID-19) (1),
48 which emerged in Wuhan, China, is caused by a novel coronavirus named severe
49 acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (2-4). As of March 1, 2020,
50 more than 80,000 laboratory-confirmed cases have been reported in China (5), and the
51 disease has spread over 58 countries in Asia, Australia, Europe, and North America
52 (1). On January 30, 2020, the WHO declared the outbreak of COVID-19 a Public
53 Health Emergency of International Concern (PHEIC).

54 SARS-CoV-2 is the seventh member of enveloped, positive-stranded RNA viruses
55 (4) that are able to infect humans. Genomic characterization of SARS-CoV-2
56 identified it as a Beta coronavirus and showed it is closely related (with 96% identity)
57 to Bat CoV RaTG13, but distinct from SARS-CoV (6). SARS-CoV-2 has a
58 receptor-binding domain (RBD) structure similar to that of SARS-CoV. Functionally
59 important ORFs (ORF1a and ORF1b) and major structural proteins, including the
60 spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins, are also well
61 annotated (7). According to previous reports, the M and E proteins are necessary for
62 virus assembly (8, 9). The S protein is important for attachment to host cells, where
63 the RBD of S protein mediates the interaction with angiotensin-converting enzyme 2
64 (ACE2) (6). The S protein is located on the surface of the viral particles and has been
65 reported to be highly immunogenic (10). The N protein is one of the major structural
66 proteins of the virus and is involved in the transcription and replication of viral RNA,
67 packaging of the encapsidated genome into virions (11, 12), and interference with cell

68 cycle processes of host cells (13). Moreover, in many coronaviruses, including
69 SARS-CoV, the N protein has high immunogenic activity and is abundantly expressed
70 during infection (14-16). Both S and N proteins may be potential antigens for
71 serodiagnosis of COVID-19, just as many diagnostic methods have been developed
72 for diagnosing SARS based on S and/or N proteins (10, 14-17).

73 Currently, diagnosis of COVID-19 is confirmed by RNA tests with real-time
74 (RT)-PCR or next-generation sequencing. Studies have shown that SARS-CoV-2
75 mainly infects the lower respiratory tract, and that viral RNA can be detected from
76 nasal and pharyngeal swabs and bronchoalveolar lavage (BAL) (3, 6, 18). However,
77 the collection of the lower respiratory samples (especially BAL) requires both a suction
78 device and a skilled operator. A previous study showed that except for BAL, the sputum
79 from confirmed patients possessed the highest positive rate, ranging from 74.4% to
80 88.9%. The positive rate of nasal swabs ranged from 53.6% to 73.3%, and throat swabs
81 collected ≥ 8 days post-disease onset (d.p.o.) had a low positive rate, especially in
82 samples from mild cases (19). The viral colonization of the lower respiratory tract and
83 the collection of different respiratory specimens cause a high false negative rate of real
84 time Reverse Transcription-Polymerase Chain Reaction (RT-PCR) diagnosis.

85 Therefore, with the current tests it is difficult to achieve a meaningful assessment of
86 the proportion of symptomatic patients that are infected, and a rapid and accurate
87 detection method of COVID-19 is urgently needed. Serological assays are accurate
88 and efficient methods for the screening for many pathogens, as specific IgM and IgG
89 antibodies can be detected with ELISA, which has relatively high throughput capacity

90 and less stringent specimen requirements (uniformly serum collection) than
91 RNA-based assays.

92 The present study was conducted to evaluate the performance of rN-based and
93 rS-based ELISAs to detect IgM and IgG antibodies in human serum against
94 SARS-CoV-2. A total of 214 clinical serum samples from confirmed COVID-19
95 patients and 100 samples from healthy blood donors were tested with the rN-based
96 and rS-based ELISAs.

97

98 **Materials and Methods**

99 **Patients and samples**

100 A total of 214 patients diagnosed with COVID-19, hospitalized in the General
101 Hospital of the Central Theater Command of the People's Liberation Army (PLA)
102 between January 18 and February 26, 2020, were recruited. The general information
103 was extracted from electronic medical records. All of the patients were
104 laboratory-confirmed positive for SARS-CoV-2 by RT-PCR using pharyngeal swab
105 specimens, and at a median of 15 d.p.o. (range, 0–55 days). Serum samples from 100
106 healthy blood donors were selected as controls. This study was approved by the
107 Hospital Ethics Committee of the General Hospital of the Central Theater Command
108 of the PLA ([2020]003-1) and the written informed consent was waived for emerging
109 infectious diseases.



110 **rN-based ELISA**

111 The recombinant nucleocapsid (rN) protein-based ELISA kit (Lizhu, Zhuhai,
112 China) was used for the detection of IgM or IgG antibody against SARS-CoV-2. For
113 IgM detection, ELISA plates were coated with monoclonal mouse anti-human IgM (μ
114 chain) antibody. Serum sample (100 μ L, diluted 1:100) was added to the pre-coated
115 plates, and plates were incubated at 37 °C for 1 h. Three replicates of each sample or
116 control were included on each plate. After washing, 100 μ L horseradish peroxidase
117 (HRP)-conjugated rN protein of SARS-CoV-2 was added. Then, the plate was
118 incubated at 37 °C for 30 min, followed by washing. TMB substrate solution (50 μ L)
119 and the corresponding buffer (50 μ L) were added, and samples were incubated at
120 37 °C for 15 min. The reaction was terminated by adding 50 μ L of 2 M sulfuric acid,
121 and the absorbance value at 450 nm (A_{450}) was determined. The cutoff value was
122 calculated by summing 0.100 and the average A_{450} of negative control replicates.
123 When A_{450} was below the cutoff value, the test was considered negative, and when
124 A_{450} was greater than or equal to the cutoff value, the test was considered positive.

125 For IgG detection, ELISA plates were coated with rN protein. Serum sample (5 μ L)
126 diluted in 100 μ L dilution buffer was added to the plates. After incubation and
127 washing, HRP-conjugated monoclonal mouse anti-human IgG antibody was added to
128 the plates for detection. The other operation steps were performed as described above
129 for IgM detection. The cutoff value was calculated by summing 0.130 and the average
130 A_{450} of negative control replicates. When A_{450} was below the cutoff value, the test was
131 considered negative, and when A_{450} was greater than or equal to the cutoff value, the
132 test was considered positive.

133 **rS-based ELISA**

134 The rS-based ELISA kit (Hotgen, Beijing, China) was developed based on the
135 RBD of the recombinant S polypeptide (rS). For IgM antibody testing, serum samples
136 (diluted 1:100) and negative and positive controls were added to the wells of the
137 rS-coated plates in a total volume of 100 μ L, and plates were incubated at 37 $^{\circ}$ C for
138 30 min. After five wash steps with washing buffer, 100 μ L of diluted HRP-conjugated
139 anti-human IgM antibodies was added to the wells, and samples were incubated at 37 $^{\circ}$ C
140 for 30 min. After five wash steps with washing buffer, 50 μ L of TMB substrate
141 solution and 50 μ L of the corresponding buffer were added, and samples were
142 incubated at 37 $^{\circ}$ C for 10 min. The reaction was terminated by adding 50 μ L of 2 M
143 sulfuric acid, and A_{450} was measured. The IgG antibody was determined by a standard
144 ELISA procedure as described above, except that serum sample was diluted 1:20, and
145 the detector was HRP-conjugated anti-human IgG. The cutoff values of IgM and IgG
146 were calculated by summing 0.250 and the average A_{450} of negative control replicates.
147 When A_{450} was below the cutoff value, the test was considered negative, and when
148 A_{450} was greater than or equal to the cutoff value, the test was considered positive.

149 **Statistical analysis**

150 Categorical variables were expressed as the counts and percentages and compared
151 using the chi-square test, while the Fisher exact test was used when the data were
152 limited. Statistical analyses were performed using SPSS version 22.0. A two-sided
153 P -value < 0.05 was considered statistically significant.

154

155 Results

156 Performance of serological assays by rN-based and rS-based ELISA

157 The serum samples were collected from 214 COVID-19 patients who were
158 confirmed by qRT-PCR and hospitalized in the General Hospital of the Central
159 Theater Command of the PLA. Of the 214 serum samples, 146 (68.2%) and 150
160 (70.1%) were identified as positive by the rN-based IgM and IgG ELISAs (Table 1),
161 respectively. IgM and/or IgG means that one of them or both were detected in serum
162 samples; 172 (80.4%) serum samples were positive by rN-based ELISA (Fig. 1). The
163 numbers of positive results with IgM, IgG, and IgM and/or IgG detected by rS-based
164 ELISA were 165 (77.1%), 159 (74.3%), and 176 (82.2%), respectively (Table 1 and
165 Fig. 1).

166 To study the production of antibodies in COVID-19 patients, we analyzed the
167 positive rates of IgM and IgG in serum samples of all patients post-disease onset.
168 Based on the number of days from disease onset to serum collection, patients were
169 divided into seven groups: 0–5, 6–10, 11–15, 16–20, 21–30, 31–35, and >35 d.p.o.
170 The median number of d.p.o. of serum sample collection was 15 (range, 0–55 days).
171 The positive rates of IgM and IgG detected by the rN- and rS-based ELISAs in
172 different groups are shown in Table 1. For rN-based ELISA, a clear increase in IgM
173 and IgG positive rates was observed (Fig. 2a). The positive rates of IgM and IgG were
174 low at 0–5 d.p.o. and 6–10 d.p.o., and the positive rate of IgM was higher than that of
175 IgG at 6–10 d.p.o. and much lower after 35 d.p.o. (Fig. 2a), illustrating the dynamic
176 pattern of acute viral infection where IgG concentrations rise as IgM levels drop. The

177 IgM and/or IgG positive rate was 88.9% at 11–15 d.p.o., and more than 90% at later
178 stages of the disease (Table 1).

179 For rS-based ELISA, a similar trend of IgM and IgG positive rates was observed
180 (Fig. 2b). The positive rate of IgM is a little higher than that of IgG at different
181 disease stages, except >35 d.p.o., possibly due to the higher sensitivity of rS-based
182 IgM detection (77.1%) than IgG detection (74.3%) (Table 1).

183 To verify the specificity of the ELISA assays, 100 samples from healthy blood
184 donors were analyzed. No positive result was found in both rN- and rS-based IgM and
185 IgG ELISAs.

186 **Comparison of rN- and rS-based IgM and IgG ELISAs for diagnosis of** 187 **SARS-CoV-2**

188 The sensitivity of the rS-based IgM ELISA was significantly higher than that of
189 the rN-based ELISA ($P < 0.05$). No significant difference between rS- and rN-based
190 ELISAs was observed for detecting IgG and total antibodies (IgM and IgG) (Fig. 1).

191 The positive rates of the rN- and rS-based ELISAs for the detection of IgM and/or
192 IgG in serum samples collected from patients at different stages of the disease are
193 shown in Table 1. Within 15 d.p.o., for detecting IgM, which is an important marker
194 for early infection, rN- and rS-based ELISAs detected 57.9% (66/114) and 63.2%
195 (72/114) of patients, indicating that the performance of the rS-based IgM
196 immunoassay seems better than that of the rN-based assay, but there is no statistical
197 difference between the two results. The positive rate of the rS-based ELISA for IgM is
198 significantly higher than that of the rN-based ELISA at 16–20 d.p.o.(Table 1). No

199 significant difference between the two antigen-based ELISAs was observed for IgM
200 detection in other groups. For IgG detection, there was no significant difference
201 between the two kits in all groups.

202 In this study, the rN- and rS-based ELISAs for detecting IgM and IgG in 214
203 COVID-19 patients were evaluated (Table 2). In total, the detected positive rate
204 (174/214, 81.3%) for IgM by the two kits was significantly higher than that of the
205 rN-based ELISA kit alone (68.2%; $P < 0.01$), but was not significantly different from
206 that of the rS-based kit alone. For IgG, 172 of 214 (80.4%) were identified positive by
207 both kits. This sensitivity is significantly higher than that detected by only the
208 rN-based ELISA (70.1%, $P < 0.05$) and is not significantly different from that of the
209 rS-based ELISA.

210

211 **Discussion**

212 The recent outbreak and rapid spread of the novel coronavirus SARS-CoV-2 pose
213 a great threat of a pandemic outbreak of COVID-19 to the world. Diagnostic methods
214 are the frontline strategy for recognizing this disease. Currently, SARS-CoV-2 can be
215 detected using RT-PCR, but inadequate access to reagents and equipment, the
216 requirement to upscale lab facilities with restrictive bio-safety levels and technical
217 sophistication, and the high rate of false negative results caused mainly by an
218 unstandardized collection of respiratory specimens have resulted in low efficiency of
219 in-time detection of the disease. Although previous studies have shown that
220 virus-specific IgM and IgG levels allow for serologic diagnosis of SARS (15, 20), less

221 amount of data on the serologic diagnosis using antibodies against SARS-CoV-2 are
222 available.

223 In this study, we evaluated immunoassays for the detection of antibodies against
224 SARS-CoV-2. Specifically, we evaluated IgM and IgG production and their diagnostic
225 value. rN- and rS-based ELISAs were used to detect IgM and IgG in serum samples
226 of confirmed COVID-19 patients. The results revealed that the rS-based ELISA is
227 more sensitive than the rN-based one in the detection of IgM antibodies (Fig. 1). We
228 speculate that this difference is due to the relatively high sensitivity and early
229 response to the S antigen compared to the N antigen in patients with COVID-19. We
230 divided the patients into different groups according to the number of d.p.o. and
231 observed an increase in the IgM and IgG positive rate with time, except the IgM
232 positive rate decreased at >35 d.p.o. (Fig. 2). This dynamic pattern is consistent with
233 that observed in acute viral infection, with the IgG concentration rising gradually as
234 IgM levels drop after one month post-disease onset. The positive rates of IgM and IgG
235 antibodies in samples tested by the rN- and rS-based ELISAs were about 30%–50% in
236 the 0–5 d.p.o. and 6–10 d.p.o. groups (Table 1 and Fig. 2). This may be due to the low
237 antibody titers in early stages of the disease. Our results showed that IgM and/or IgG
238 of SARS-CoV-2 might be positive (88.9% by rN-based ELISA, 90.7% by rS-based
239 ELISA) at 11–15 d.p.o. (Table 1), which is to a certain extent in accordance with a
240 previous publication about SARS, which reported that detection of antibodies to
241 SARS-CoV could be positive as early as 8–10 d.p.o. and often occurs around day 14
242 (15). We observed a decreased positive rate of IgM at > 35 d.p.o.; unfortunately, we

243 could not collect the samples from these patients after discharge. Combined, rN- and
244 rS-based ELISAs for IgM and IgG detection were more sensitive than the rN-based
245 ELISA alone, but there was no significant difference when compared with the
246 rS-based ELISA. Therefore, combined use of rN- and rS-based ELISAs is not
247 recommended for COVID-19 diagnosis; however, if an ELISA kit coated with a
248 cocktail of N and S polypeptides shows better results, further evaluation is needed.

249 This study demonstrated that rN- and rS-based ELISAs can be an important
250 screening method for COVID-19 diagnosis, with high sensitivity, especially for the
251 analysis of serum samples from patients after more than 10 d.p.o. However, the
252 rS-based immunoassay is recommended for early screening of suspected COVID-19
253 patients with negative PCR test results. The ELISA serodiagnosis can be a
254 supplementary method to RT-PCR for COVID-19 diagnosis. ELISA can be used to
255 quickly screen all febrile patients effectively, as large-scale confirmation or exclusion
256 of patients is essential for controlling the disease.

257

258 **Acknowledgments**

259 We appreciate the helpful advice from professor Ruifu Yang from the Beijing
260 Institute of Microbiology and Epidemiology regarding this work and his revision of
261 this manuscript. This work was supported by the National Natural Science Foundation
262 of China (81801984), the China Postdoctoral Science Foundation (2019M664008),
263 and the Wuhan Young and Middle-aged Medical Backbone Talents Training Project
264 (Wuweitong [2019] 87th). We thank all healthcare workers involved in this study. We

265 thank LetPub (www.letpub.com) for its linguistic assistance during the preparation of
266 this manuscript.

267

268 **Conflict of interest**

269 The authors declare that no conflict of interest exists.

270 **Authors' contributions**

271 S.Z. and W.L. conceived the study and designed experimental procedures. L.L.,
272 G.K., Y.Z., Y.D., W.N., Q.W., L.T., W.W., S.T., and Z.X. collected patients' samples.
273 L.L. and G.K. established the ELISA and performed serological assays. W.L., S.Z.,
274 and L.L. wrote the paper. All authors contributed to data acquisition, data analysis,
275 and/or data interpretation, and reviewed and approved the final version.

276

277 **References**

- 278 1. WHO. Coronavirus disease 2019.
279 <https://www.who.int/emergencies/diseases/novel-coronavirus-2019>. Accessed
- 280 2. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, Xing F, Liu J, Yip CC, Poon RW, Tsoi HW,
281 Lo SK, Chan KH, Poon VK, Chan WM, Ip JD, Cai JP, Cheng VC, Chen H, Hui CK, Yuen KY.
282 2020. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating
283 person-to-person transmission: a study of a family cluster. *Lancet*
284 doi:10.1016/S0140-6736(20)30154-9.
- 285 3. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T,
286 Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang
287 R, Gao Z, Jin Q, Wang J, Cao B. 2020. Clinical features of patients infected with 2019 novel
288 coronavirus in Wuhan, China. *Lancet* doi:10.1016/S0140-6736(20)30183-5.
- 289 4. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan
290 F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W. 2020. A Novel Coronavirus from Patients
291 with Pneumonia in China, 2019. *N Engl J Med* doi:10.1056/NEJMoa2001017.
- 292 5. Anonymous. 2020. National Health Commission of the People's Republic of China. The
293 latest situation of novel coronavirus pneumonia as of 24:00 on March 1, 2020.
294 <http://www.nhc.gov.cn/xcs/yqtb/202003/5819f3e13ff6413ba05fdb45b55b66ba.shtml>.
295 Accessed
- 296 6. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen

- 297 HD, Chen J, Luo Y, Guo H, Jiang RD, Liu MQ, Chen Y, Shen XR, Wang X, Zheng XS, Zhao
298 K, Chen QJ, Deng F, Liu LL, Yan B, Zhan FX, Wang YY, Xiao GF, Shi ZL. 2020. A
299 pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature*
300 doi:10.1038/s41586-020-2012-7.
- 301 7. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, Bi Y, Ma X,
302 Zhan F, Wang L, Hu T, Zhou H, Hu Z, Zhou W, Zhao L, Chen J, Meng Y, Wang J, Lin Y, Yuan
303 J, Xie Z, Ma J, Liu WJ, Wang D, Xu W, Holmes EC, Gao GF, Wu G, Chen W, Shi W, Tan W.
304 2020. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for
305 virus origins and receptor binding. *Lancet* doi:10.1016/S0140-6736(20)30251-8.
- 306 8. Neuman BW, Kiss G, Kunding AH, Bhella D, Baksh MF, Connelly S, Droese B, Klaus JP,
307 Makino S, Sawicki SG, Siddell SG, Stamou DG, Wilson IA, Kuhn P, Buchmeier MJ. 2011. A
308 structural analysis of M protein in coronavirus assembly and morphology. *J Struct Biol*
309 174:11-22.
- 310 9. Nieto-Torres JL, DeDiego ML, Verdia-Baguena C, Jimenez-Guardeno JM, Regla-Nava JA,
311 Fernandez-Delgado R, Castano-Rodriguez C, Alcaraz A, Torres J, Aguilella VM, Enjuanes L.
312 2014. Severe acute respiratory syndrome coronavirus envelope protein ion channel activity
313 promotes virus fitness and pathogenesis. *PLoS Pathog* 10:e1004077.
- 314 10. Woo PC, Lau SK, Wong BH, Tsoi HW, Fung AM, Kao RY, Chan KH, Peiris JS, Yuen KY.
315 2005. Differential sensitivities of severe acute respiratory syndrome (SARS) coronavirus spike
316 polypeptide enzyme-linked immunosorbent assay (ELISA) and SARS coronavirus
317 nucleocapsid protein ELISA for serodiagnosis of SARS coronavirus pneumonia. *J Clin*
318 *Microbiol* 43:3054-8.
- 319 11. Chang CK, Sue SC, Yu TH, Hsieh CM, Tsai CK, Chiang YC, Lee SJ, Hsiao HH, Wu WJ,
320 Chang WL, Lin CH, Huang TH. 2006. Modular organization of SARS coronavirus
321 nucleocapsid protein. *J Biomed Sci* 13:59-72.
- 322 12. Hurst KR, Koetzner CA, Masters PS. 2009. Identification of in vivo-interacting domains of
323 the murine coronavirus nucleocapsid protein. *J Virol* 83:7221-34.
- 324 13. Cui L, Wang H, Ji Y, Yang J, Xu S, Huang X, Wang Z, Qin L, Tien P, Zhou X, Guo D, Chen Y.
325 2015. The Nucleocapsid Protein of Coronaviruses Acts as a Viral Suppressor of RNA
326 Silencing in Mammalian Cells. *J Virol* 89:9029-43.
- 327 14. Che XY, Qiu LW, Pan YX, Wen K, Hao W, Zhang LY, Wang YD, Liao ZY, Hua X, Cheng VC,
328 Yuen KY. 2004. Sensitive and specific monoclonal antibody-based capture enzyme
329 immunoassay for detection of nucleocapsid antigen in sera from patients with severe acute
330 respiratory syndrome. *J Clin Microbiol* 42:2629-35.
- 331 15. Chen S, Lu D, Zhang M, Che J, Yin Z, Zhang S, Zhang W, Bo X, Ding Y, Wang S. 2005.
332 Double-antigen sandwich ELISA for detection of antibodies to SARS-associated coronavirus
333 in human serum. *European Journal of Clinical Microbiology & Infectious Diseases*
334 24:549-553.
- 335 16. Guan M, Chen HY, Foo SY, Tan YJ, Goh PY, Wee SH. 2004. Recombinant protein-based
336 enzyme-linked immunosorbent assay and immunochromatographic tests for detection of
337 immunoglobulin G antibodies to severe acute respiratory syndrome (SARS) coronavirus in
338 SARS patients. *Clin Diagn Lab Immunol* 11:287-91.
- 339 17. Hsueh PR, Kao CL, Lee CN, Chen LK, Ho MS, Sia C, Fang XD, Lynn S, Chang TY, Liu SK,
340 Walfield AM, Wang CY. 2004. SARS antibody test for serosurveillance. *Emerg Infect Dis*

- 341 10:1558-62.
- 342 18. Anonymous. 2020-2-18. National Health Commission of the People's Republic of China.
343 Notice on the issuance of strategic guidelines for diagnosis and treatment of novel coronavirus
344 infected pneumonia (sixth edition draft)
345 <http://www.nhc.gov.cn/xcs/zhengcwj/202002/8334a8326dd94d329df351d7da8aefc2.shtml>.
346 Accessed
- 347 19. Yang Yang MY, Chenguang Shen, Fuxiang Wang, Jing Yuan, Jinxiu, Li MZ, Zhaoqin Wang,
348 Li Xing, Jinli Wei, Ling Peng, Gary Wong, Haixia, Zheng WW, Mingfeng Liao, Kai Feng,
349 Jianming Li, Qianting Yang, Juanjuan, Zhao ZZ, Lei Liu, Yingxia Liu. 2020. Evaluating the
350 accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the
351 viral shedding of 2019-nCoV infections, *on medRxiv*.
352 <https://doi.org/10.1101/2020.02.11.20021493>. Accessed
- 353 20. Chan PK, To WK, Liu EY, Ng TK, Tam JS, Sung JJ, Lacroix JM, Houde M. 2004. Evaluation
354 of a peptide-based enzyme immunoassay for anti-SARS coronavirus IgG antibody. *J Med*
355 *Virol* 74:517-20.
356

357 **FIGURE LEGENDS**

358 **Figure 1.** Comparison of positive rate of antibodies detected by rN-based ELISA and
359 rS-based ELISA. IgM means a positive result of IgM antibody detection by ELISA,
360 IgG means a positive result of IgG antibody detection by ELISA, IgM and/or IgG
361 means at least one of them was positive by IgM and IgG ELISA. Results were
362 compared by chi-square tests.

363

364 **Figure 2.** Dynamic trend of the positive rate of IgM and IgG in serum of patients at
365 the different stage of disease. Patients were divided into seven groups of 0-5,
366 6-10,11-15, 16-20,21-30, 31-35 and >35 days post-disease onset, **a)** The dynamic
367 trend of antibodies positive rate detected by rN-based ELISA. **b)** The dynamic trend
368 of antibodies positive rate detected by rS-based ELISA.

Table 1. Positive rate of rN-based and rS-based ELISA for detection of IgM and IgG in serum samples of patients at different stages after disease onset.

Days	No. of serum samples	No. (%) positive for IgM			No. (%) positive for IgG			No. (%) positive for IgM and/or IgG		
		rN-based	rS-based	P	rN-based	rS-based	P	rN-based	rS-based	P
Total	214	146(68.2)	165(77.1)	0.039	150(70.1)	159(74.3)	0.332	172(80.4)	176(82.2)	0.620
0-5	22	7(31.8)	8(36.4)	0.750	7(31.8)	9(40.9)	0.531	9(40.9)	10(45.5)	0.761
6-10	38	20(52.6)	19(50.0)	0.818	15(39.5)	19(50.0)	0.356	20(52.6)	23(60.5)	0.488
11-15	54	39(72.2)	45(83.3)	0.165	39(72.2)	41(75.9)	0.661	48(88.9)	49(90.7)	0.750
16-20	55	45(81.8)	53(96.4)	0.014	48(87.3)	51(92.7)	0.340	52(94.5)	53(96.4)	0.647
21-30	32	26(81.3)	28(87.5)	0.491	28(87.5)	27(84.4)	0.719	30(93.8)	28(87.5)	0.391
31-35	6	5(83.3)	6(100.0)	0.296	6(100.0)	5(83.3)	0.296	6(100.0)	6(100.0)	N/A
>35	7	4(57.1)	6(85.7)	0.237	7(100.0)	7(100.0)	N/A	7(100.0)	7(100.0)	N/A

IgM and/or IgG: at least a positive result detected by IgM and IgG ELISA

Days: Days post-disease onset.

N/A: Not available.

1 Table 2. Summary results for IgM and IgG detection in the 214 serum samples from
2 patients with COVID-19.


No. (%)	positive both rN- and rS- based ELISA	positive only by rN-based ELISA	positive only by rS-based ELISA	negative both rN- and rS-based ELISA
IgM	137(64.0)	9(4.2)	28(13.1)	40(18.7)
IgG	137(64.0)	13(6.1)	22(10.3)	42(19.6)

3

4

5 **Figures**

6





7

8 **Figure 1**

9

10



11

12 **Figure 2**